Abstract
Fenoldopam mesylate is a parenteral post-synaptic dopamine1 receptor agonist currently under FDA review for the treatment of severe hypertension. The agent markedly lowers blood pressure, augments renal blood flow secondary to a reduction in renal vascular resistance, and induces both a diuresis and natriuresis in severe hypertensive patients. Fenoldopam exhibits equivalent blood pressure control and dose-response to nitroprusside. Fenoldopam is relatively well tolerated, devoid of toxic metabolite formation, and requires no protection from light. In consideration of its physiological, clinical, and pharmaceutical advantages, fenoldopam would appear to be a useful addition to the antihypertensive armamentarium.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 453-460 |
| Number of pages | 8 |
| Journal | Hospital Formulary |
| Volume | 26 |
| Issue number | 6 |
| State | Published - 1991 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmaceutical Science
Cite this
Focus on fenoldopam : A dopaminergic agonist for severe hypertension. / Munger, M. A.; Stanek, E. J.; Panacek, Edward A.
In: Hospital Formulary, Vol. 26, No. 6, 1991, p. 453-460.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Focus on fenoldopam
T2 - A dopaminergic agonist for severe hypertension
AU - Munger, M. A.
AU - Stanek, E. J.
AU - Panacek, Edward A
PY - 1991
Y1 - 1991
N2 - Fenoldopam mesylate is a parenteral post-synaptic dopamine1 receptor agonist currently under FDA review for the treatment of severe hypertension. The agent markedly lowers blood pressure, augments renal blood flow secondary to a reduction in renal vascular resistance, and induces both a diuresis and natriuresis in severe hypertensive patients. Fenoldopam exhibits equivalent blood pressure control and dose-response to nitroprusside. Fenoldopam is relatively well tolerated, devoid of toxic metabolite formation, and requires no protection from light. In consideration of its physiological, clinical, and pharmaceutical advantages, fenoldopam would appear to be a useful addition to the antihypertensive armamentarium.
AB - Fenoldopam mesylate is a parenteral post-synaptic dopamine1 receptor agonist currently under FDA review for the treatment of severe hypertension. The agent markedly lowers blood pressure, augments renal blood flow secondary to a reduction in renal vascular resistance, and induces both a diuresis and natriuresis in severe hypertensive patients. Fenoldopam exhibits equivalent blood pressure control and dose-response to nitroprusside. Fenoldopam is relatively well tolerated, devoid of toxic metabolite formation, and requires no protection from light. In consideration of its physiological, clinical, and pharmaceutical advantages, fenoldopam would appear to be a useful addition to the antihypertensive armamentarium.
UR - http://www.scopus.com/inward/record.url?scp=0025744762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025744762&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0025744762
VL - 26
SP - 453
EP - 460
JO - Formulary
JF - Formulary
SN - 1082-801X
IS - 6
ER -